Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 262

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 262
---
. as a result of the conversion 
 of the Convertible Promissory Note we issued to Sabby Volatility Warrant Master Fund, Ltd. on May 8, 2023 (the “Sabby Note”)..        |

| ● | On July 14, 2023, we                                                                                                             
 issued a total of 488 restricted shares of our common stock to BioIntelect Pty Ltd as deferred equity compensation valued in the 
 amount of $155,000.                                                                                                              |

| ● | On July 14, 2023, we                                                                                                                 
 converted the entirety of debt owed to a noteholder to 3,583 shares of our common stock at the conversion price equal to the initial 
 public offering price, of which were issued to Xu Yu.                                                                                |

| ● | On July 14, 2023, we                                                                                                 
 issued 18,473 shares of common stock to Knight Therapeutics (Barbados) Inc.) (“Knight”) upon conversion of debt owed 
 to Knight.                                                                                                           |

| ● | On July 28, 2023, we                                                                                                                      
 issued 760 restricted shares of our common stock to Knight upon conversion of 2,162 shares of Series A Preferred Stock, at the conversion 
 rate price detailed in Note 6 to the accompanying consolidated condensed financial statements.                                            |

II-2 The issuances of shares of common stock listed above were deemed exempt from registration under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance of securities did not involve a public offering.

| ● | On                                                                                            
 the effective date of our initial public offering registration statement, we issued 1,158     
 shares of our common stock to Mountjoy Trust as a result of the conversion of the Convertible 
 Promissory Note we issued to Mountjoy Trust on May 19, 2022 (the “Mountjoy Note”).            |

| ● | From                                                                                             
 October 2024 to January 2025, we issued an aggregate of 579,711 shares of common stock upon      
 the exercise of pre-funded warrants issued to investors in the September 2025 private placement. |

The issuance of the capital stock listed above was deemed exempt from registration under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance of securities were made to an accredited investor and did not involve a public offering. The recipient of such securities represented its intention to acquire the securities for investment